Background

Aung Pyae Phyo completed a Bachelor of Medicine and Surgery at University of Medicine Yangon in 2001. He joined the Shoklo Malaria Research Unit in 2005 where he led the research which revealed the emergence of artemisinin resistance on the Thai-Myanmar border in 2010.

Afterwards, he pursued research on the Artemisinin Combination Therapy resistant malaria as well as trials of new antimalarial compounds including OZ439 (Artefenomel), KAF156 (Ganaplacide) and KAE609 (Cipargamin).

In 2017 Aung Pyae Phyo completed his Doctor of Philosophy in Clinical Medicine at the Nuffield Department of Medicine, University of Oxford. His PhD thesis title is “Defining the optimal management of Plasmodium falciparum malaria”. After completing his DPhil, he joined to Myanmar Oxford Clinical Research Unit in Yangon, Myanmar where his focus is malaria elimination and surveillance of the spread of drug resistant malaria in Greater Mekong Subregion (GMS).

In 2019, he was awarded the Wellcome Trust International Training Fellowship to continue his work on drug resistance and malaria elimination in Myanmar under the supervision of A/Prof Freya Fowkes at the Burnet Institute and Prof Sir Nicholas White at the Mahidol-Oxford Research Unit.

Positions

• 2019-current – Wellcome Trust Fellow, Burnet Institute and Myanmar Oxford Clinical Research Unity
• 2017-current- Myanmar Oxford Clinical Research Unit
• 2013-2017: D Phil Candidate, University of Oxford/ Shoklo Malaria Research Unit
• 2007-2013: Research Clinician, Shoklo Malaria Research Unit
• 2005-2007: Research Assistant, Shoklo Malaria Research Unit
• 2004-2005: Medical Officer, World Vision Foundation of Thailand
• 2002 -2004 Jul: Demonstrating Doctor, Department of Physiology, University of Medicine

Qualifications

• 2017: DPhil, University of Oxford
• 2001: MBBS, Bachelor for Medicine, Bachelor for Surgery

Awards

• 2019-2021: International Training Fellowship, the Wellcome Trust
• 2016: Travel award Genomic Epidemiology of Malaria

Publications (1)

2022 (1)

• Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia.
  Cutts JC, O'Flaherty K, Zaloumis SG, Ashley EA, Chan JA, Onyamboko MA, Fanello C, Dondorp AM, Day NP, Phyo AP, Dhorda M, Imwong M, Fairhurst RM, Lim P, Amaratunga C, Pukrittayakamee S, Hien TT, Htut Y, Mayxay M, Abdul Faiz M, Takashima E, Tsuboi T, Beeson JG, Nosten F, Simpson JA, White NJ, Fowkes FJI
  J Infect Dis. 2022 Jun; 226(2):324-331